Centivax signs licensing agreement with Thermo Fisher for its anti-COVID-19 antibodies
Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today a licensing agreement with Thermo Fisher Scientific. Thermo Fisher has developed and evaluated several variants of Centivax’s highly specific and effective therapeutic antibody candidates against COVID-19 for use in research, including flow cytometry, histopathology, in vitro and in vivo neutralization, Luminex…